KYORIN Pharmaceutical Co.,Ltd. stock analysis
Want to see JP:4569 full AI Analyst Report?
Low leverage and continued equity growth provide financial flexibility to absorb earnings volatility, fund pharmaceutical development, and maintain operations without excessive dependence on external borrowing.
The multi-year revenue trend indicates an established commercial platform and recurring demand for the company’s prescription medicines. This provides a foundation for recovery if product volumes, market share, or portfolio mix improve.
The return to positive free cash flow and stronger operating cash generation supports ongoing investment in R&D and commercialization. Although consistency remains limited, the latest improvement provides some funding capacity without relying solely on financing.
The latest revenue contraction interrupts the prior multi-year upward trend and may indicate weaker prescription demand, product mix pressure, competition, or reimbursement effects. Sustained declines would reduce operating leverage and constrain investment capacity.
Sharp compression across gross and net margins demonstrates increased sensitivity to costs, product mix, pricing, or lower sales volume. Persistently weaker profitability could limit returns on R&D and reduce funds available for portfolio renewal.
Several years of negative free cash flow followed by only a modest rebound indicate inconsistent cash conversion and possible variability in investment or working-capital needs. This makes long-term funding for development and shareholder distributions less predictable.
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has provided an update. KYORIN Pharmaceutical Co., Ltd., a TSE Prime-listed Japanese pharmaceutical manufacturer, develops and markets prescription pharmaceuticals and healthcare-related products. Its shares
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has provided an announcement. KYORIN Pharmaceutical has signed a definitive agreement to transfer its generic drug business, including subsidiary KYORIN Rimedio and two manufacturing
An announcement from KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) is now available. KYORIN Pharmaceutical will begin promotion of Alesion eyelid cream 0.5%, a once-daily, long-acting treatment for allergic conjunctivitis, from
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has issued an update. KYORIN Pharmaceutical Co., Ltd., a Japan-based drug manufacturer, specializes in developing and selling prescription pharmaceuticals while maintaining an active pipeline
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has issued an announcement. KYORIN Pharmaceutical reported consolidated net sales of ¥29.65 billion for the three months ended June 30, 2026, down 1.9% year
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has shared an announcement. KYORIN Pharmaceutical has entered a joint marketing agreement in Japan with ophthalmology specialist Santen Pharmaceutical for Alesion eyelid cream 0.5%,
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) has shared an announcement. KYORIN Pharmaceutical has approved a partial revision of its performance-linked stock compensation plan, which was originally introduced in 2016 and
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) just unveiled an announcement. KYORIN Pharmaceutical Co., Ltd. has announced a reshuffle of its governance structure, including new director and auditor appointments effective June
KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) just unveiled an announcement. KYORIN Pharmaceutical has unveiled its new medium-term business plan, “Vision 110 – Stage 2 –,” covering fiscal years 2026 to
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 5 | 0 | 7 |
